Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Protalix BioTherapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Protalix BioTherapeutics, Inc.’s stock price such as:

• Protalix BioTherapeutics, Inc.’s current stock price and volume
• Why Protalix BioTherapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for PLX from analysts
• PLX’s stock price momentum as measured by its relative strength

About Protalix BioTherapeutics, Inc. (PLX)

Before we jump into Protalix BioTherapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.

Want to learn more about Protalix BioTherapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Protalix BioTherapeutics, Inc..

Protalix BioTherapeutics, Inc.’s Stock Price as of Market Close

As of September 03, 2026, 10:57 AM, CST, Protalix BioTherapeutics, Inc.’s stock price was $2.575.

Protalix BioTherapeutics, Inc. is down 0.58% from its previous closing price of $2.590.

During the last market session, Protalix BioTherapeutics, Inc.’s stock traded between $2.570 and $2.610. Currently, there are approximately 79.99 million shares outstanding for Protalix BioTherapeutics, Inc..

Protalix BioTherapeutics, Inc.’s price-earnings (P/E) ratio is currently at 11.0, which is low compared to the Biotechnology industry median of 20. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Protalix BioTherapeutics, Inc. Stock Price History

Protalix BioTherapeutics, Inc.’s (PLX) price is currently up 0.19% so far this month.

During the month of September, Protalix BioTherapeutics, Inc.’s stock price has reached a high of $2.670 and a low of $2.565.

Over the last year, Protalix BioTherapeutics, Inc. has hit prices as high as $3.190 and as low as $1.520. Year to date, Protalix BioTherapeutics, Inc.’s stock is up 43.06%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Protalix BioTherapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 02, 2026, there were analysts who downgraded Protalix BioTherapeutics, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Protalix BioTherapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Protalix BioTherapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Protalix BioTherapeutics, Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Protalix BioTherapeutics, Inc. (PLX) by visiting AAII Stock Evaluator.

Relative Price Strength of Protalix BioTherapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 02, 2026, Protalix BioTherapeutics, Inc. has a weighted four-quarter relative price strength of 17.05%, which translates to a Momentum Score of 90 and is considered to be Very Strong.

Want to learn more about how Protalix BioTherapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Protalix BioTherapeutics, Inc. Stock Price: Bottom Line

As of September 3, 2026, Protalix BioTherapeutics, Inc.’s stock price is $2.575, which is down 0.58% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Protalix BioTherapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.